The purpose of this study is to determine a safe and effective dose of a new contrast agent, P03277, developed by Guerbet and not yet approved by the FDA. It will be compared to another contrast agent, MultiHance®, which is approved by the FDA, to assess the the dose that will allow the best contrast of images and its if this dose is well tolerated by subjects. Subjects must be scheduled to undergo a routine MRI of their brain or spine with injection of a contrast agent. They must have at least one lesion of a minimum of 5 mm identified on a previous scan. The study will include a maximum of 5 study visits, the minimum time of participation is 4 days and the maximum is 22 days.